Eric Wang

Eric Wang

Auto-generated profile, based on publicly available information

Eric Wang

Daiichi-Sankyo, Inc., Basking Ridge, NJ 07920, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2022 in Future Oncology
Verified
Journal Article
Open access
CDCharles Dharmani
Charles Dharmani
EWEric Wang
Eric Wang
MSMaribel Salas
Maribel Salas
CMColleen McCabe
Colleen McCabe
ADAlvileen Diggs
Alvileen Diggs
VKVicki L Keedy
Vicki L Keedy
For drugs with enhanced serious safety risks, Risk Evaluation and Mitigation Strategy (REMS) may be required. Pexidartinib is approved for treatment of adult symptomatic tenosynovial giant cell tum... Plain language summary For drugs with serious side effects, specific safety measures may be put in place to manage these serious side effects in the form of Risk Evaluation and Mitigation Strategy ...

1 January 2023 in Future Oncology
Verified
Journal Article
Open access
CDCharles Dharmani
Charles Dharmani
EWEric Wang
Eric Wang
NTNora Tu
Nora Tu
MSMaribel Salas
Maribel Salas
YKYasser Mostafa Kamel
Yasser Mostafa Kamel
Background: Without treatment, acute myeloid leukemia (AML) is rapidly fatal. Nevertheless, a large proportion of elderly AML patients do not receive any treatment. Aim: To characterize the demogra... Plain language summary An analysis of the data collected in the Surveillance, Epidemiology and End Results-Medicare database from 2008 to 2015 was performed. This database includes data collected b...

8 November 2024 in Diabetologia
Verified
Journal Article
Open access
PDF file
EWEric Wang
Eric Wang
EPElisabetta Patorno
Elisabetta Patorno
FKFarzin Khosrow-Khavar
Farzin Khosrow-Khavar
SCStephen Crystal
Stephen Crystal
CDChintan V. Dave
Chintan V. Dave
Aims/hypothesis: The aim of this study was to investigate racial and ethnic disparities in the use of sodium–glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor antagonists (GLP-1RAs) among older adults with type 2 diabetes and cardiorenal conditions. Methods: Using Medicare fee-for-service data (2013–2019), this retrospective cohort study identified older adults (≥65 years) with type 2 diabetes initiating second-line therapies (SGLT2is, GLP1-RAs, dipeptidyl peptidase-4 inhibitors [DPP4is] and sulfonylureas [SUs]) with (1) heart failure (HF), (2) atherosclerotic cardiovascular disease (ASCVD), (3) chronic kidney disease (CKD) and (4) no recorded cardiorenal conditions. Participants were classified as non-Hispanic White, non-Hispanic Black and Hispanic. Multinomial regressions, adjusting for sociodemographic, clinical and county-level characteristics, were used to model the odds of initiating SGLT2is or GLP-1RAs within each cohort. Results: Black participants with HF, ASCVD, CKD or no recorded cardiorenal conditions had 35% (adjusted OR 0.65 [95% CI 0.61, 0.68]), 33% (0.67 [0.64, 0.69]), 32% (0.68 [0.64, 0.72]) and 24% (0.76 [0.74, 0.79]) lower odds of initiating SGLT2is, respectively, than White participants. Disparities ameliorated from 50–60% lower odds in 2013 to 17–18% in 2019. Similar patterns were observed for GLP-1RA uptake among Black participants. By contrast, Hispanic participants had similar odds of SGLT2i initiation in the HF and CKD cohorts as White participants, but 6% (0.94 [0.91, 0.98]) lower odds in the ASCVD cohort. Notable disparities for Hispanic participants compared with White participants were observed for GLP-1RA uptake in the HF, ASCVD, CKD and no cardiorenal conditions cohorts: 11% (0.89 [0.84, 0.94]), 16% (0.84 [0.81, 0.87]), 16% (0.84 [0.80, 0.89]) and 25% (0.75 [0.72, 0.78]) lower odds, respectively. Participants had greater odds than White participants of initiating DPP4is, which confer no cardiorenal benefits, across all cohorts (HF 1.25 [1.19, 1.31]; ASCVD 1.36 [1.32, 1.40]; CKD 1.32 [1.26, 1.38). Adjustment for social determinants of health did not meaningfully change the study findings. Conclusions/interpretation: Compared with White participants, disparities in the uptake of SGLT2is were evident for Black participants, and in the uptake of GLP-1RAs for both Black and Hispanic participants. This study highlights how type 2 diabetes management is evolving, while underscoring historical imbalances that have shown signs of abatement. Graphical

15 March 2024 in Biomarkers in Medicine
Verified
Journal Article
Closed access
EWEric Wang
Eric Wang
MHMackenzie Henderson
Mackenzie Henderson
PYPriyanka Yalamanchili
Priyanka Yalamanchili
JCJenilee Cueto
Jenilee Cueto
ZIZahidul Islam
Zahidul Islam
MSMaribel Salas
Maribel Salas
Breast cancer treatments have evolved rapidly, and clinically meaningful biomarkers have been used to guide therapy. These biomarkers hold utility within the drug development process to increase th...

21 February 2024 in Future Oncology
Verified
Journal Article
Open access
CDCharles Dharmani
Charles Dharmani
OFOluwatosin Fofah
Oluwatosin Fofah
EWEric Wang
Eric Wang
MSMaribel Salas
Maribel Salas
MWMargaret Wooddell
Margaret Wooddell
GTGabriel Tinoco
Gabriel Tinoco
Aim: Real-world treatment patterns in tenosynovial giant cell tumor (TGCT) patients remain unknown. Pexidartinib is the only US FDA-approved treatment for TGCT associated with severe morbidity or f... Plain language summary – Treatment patterns in patients with tenosynovial giant cell tumors in the USA This database study is the first investigation of how drugs are used to treat patients with te...

22 June 2023 in Future Oncology
Verified
Journal Article
Open access
CDCharles Dharmani
Charles Dharmani
EWEric Wang
Eric Wang
NTNora Tu
Nora Tu
OFOluwatosin Fofah
Oluwatosin Fofah
JCJenilee Cueto
Jenilee Cueto
YKYasser Mostafa Kamel
Yasser Mostafa Kamel
Aim: Elderly acute myeloid leukemia (AML) patients are often not treated with antileukemic therapy due to their poor overall health condition, leaving supportive care as the sole treatment option. ... Plain language summary - Elderly patients with acute myeloid leukemia who only receive supportive care in the Surveillance, Epidemiology and End Results-Medicare database: demographics, treatment p...